Allergic BronchoPulmonary Aspergillosis in Nepal

Neha Agarwal,1 Prajowel Shrestha,1 Ramesh Chokhani1

1Department of Pulmonary Medicine, Norvic International Hospital, Kathmandu, Nepal.

ABSTRACT

Allergic BronchoPulmonary Aspergillosis (ABPA) is clinically under recognized and often misdiagnosed in Nepal. A total of 15 cases of ABPA were enrolled in this case series. Cases were followed up after the 3 months of start of treatment and clinical responses were assessed. The mean age of the patients was 33.06 ± 9.2 yrs. 80% were male. 26.6% patients were empirically on anti-tubercular treatment at the time of presentation. 40% patients were misdiagnosed and already treated as pulmonary Tuberculosis. 10 patients were previously treated as cases of refractory asthma. Majority of patients had significant eosinophilia and raised total serum IgE. All patients required treatment with bronchodilator and systemic steroid. 80% patients underwent remission with the treatment. Pulmonary Tuberculosis and refractory bronchial asthma are common condition that leads to the misdiagnosis of this disease.

Keywords: ABPA; bronchial asthma; central bronchiectasis; eosinophil count; serum IgE.

INTRODUCTION

Allergic BronchoPulmonary Aspergillosis (ABPA) is a pulmonary disorder caused by immunologic reactions to antigens released by Aspergillus fumigatus, colonizing the airways of patients with asthma and cystic fibrosis. Clinically, ABPA presents with uncontrolled asthma, expectoration of mucus plugs, fleeting pulmonary opacities and bronchiectasis.2,3 The diagnosis of ABPA is currently made on the basis of Rosenberg Patterson criteria which is combination of clinical, radiological and immunological findings.4,6 ABPA is clinically under recognized and often misdiagnosed in Nepal. The main objective of this study is to highlight the some salient clinical features, diagnosis and treatment together with some demographic profile of this disease in our context.

METHODS

A total of 15 cases of ABPA were enrolled. Cases were enrolled both retrospectively and prospectively from the day 1 of study period. Rosenberg and Patterson criterion was used for the diagnosis of ABPA. Prospective cases were followed up after the 3 months of start of treatment and clinical response was assessed.

The mean age of the patients was 33.06 ± 9.2 yrs (Mean ± SD). 12 patients (80%) were male and 3 patients (20%) were female. Clinical characteristics of patients are outlined in Table no. 1. Cough and fever was the most common presenting clinical feature. Classically described brownish colored sputum was

Correspondence: Dr Ramesh Chokhani, Norvic International Hospital, Thapathali, Kathmandu, Nepal. Email: ramesh_chokhani@yahoo.co.in, Phone: +977 9851043632
present in 80% of patients. 53.3% of patients also had hemoptysis at the time of presentation. Majority of patients had wheeze and Inspiratory crackles on chest examination. Out of 15 patients, 4 patients (26.6%) were empirically on anti-tubercular treatment at the time of presentation. A total of 6 patients (40%) were misdiagnosed and already treated as pulmonary Tuberculosis. Ten patients were treated as cases of refractory asthma before presenting to our OPD.

Majority of patients (73.3%) had absolute eosinophil count more than 1000 at the time of presentation. All patient had significantly elevated (>1000) Total serum IgE level. Similarly all the 15 patients had positive Aspergillus specific IgE.

The findings of chest x-ray and high resolution computed tomography (HRCT) scan of chest are highlighted in Table no. 2. Central bronchiectasis (Fig.1) was present in 12 patients (80%). Mucus plugs and centrilobular nodules were present in 60% and 66.6% of patients respectively.

All 15 patients required treatment with bronchodilator and systemic steroid. Itraconazole was required in three patients (20%) due to frequent relapse. On follow up 14 out of 15 patients i.e. 93.3% of patients had some radiological clearing of the pulmonary opacity. Total serum IgE decline was more than 50% in 13 patients (86.6%). Out of 15 enrolled patients 12 patients (80%) underwent remission with the treatment whereas three patients had frequent relapses in their clinical course. Treatment and outcomes are highlighted in Table no. 3.

**DISCUSSION**

ABPA is an allergic pulmonary disorder caused by hypersensitivity to Aspergillus fumigatus clinically manifesting as chronic asthma, recurrent pulmonary infiltrates, fever, brownish expectoration and bronchiectasis.\(^3\)\(^6\)

The problem is not well recognized in Nepal. There is only one case report published by one of the investigators of this study.\(^7\)

The Rosenberg-Patterson criteria form the basis of a diagnosis of ABPA, with the presence of six of the following criteria making the diagnosis of ABPA almost certain: presence of asthma, current or previous infiltrates on chest radiograph or CT, immediate cutaneous reactivity to Aspergillus using a skin-prick test or intradermal injection, elevated total serum IgE
had history of treatment for Pulmonary Tuberculosis.

This problem has been highlighted in other previous case series on ABPA. Agrawal et al, in their large case series, hemoptysis was observed in 37 to 69% of patients with ABPA.

The mean age of patient in our study group was 33.06 ± 9.2 years. The reported mean age group in two largest case series on ABPA from India is 34.4 and 32 years respectively. The most common symptoms in our group of patients were cough, production of sputum, brownish coloured sputum and hemoptysis. The reported incidence of hemoptysis in ABPA is 44.4% and production of brownish coloured sputum is 47.6% by Agrawal et al in 2006 and 2007. In other large case series, hemoptysis was observed in 37 to 69% of patients with ABPA.

Fever is another common clinical presentation of ABPA; fever was present in 66% of our patients. Fever has been reported in 80% of patients with ABPA.

ABPA is often misdiagnosed as pulmonary Tuberculosis due to its pulmonary symptoms. Presence of cough and hemoptysis together with fever, pulmonary infiltrates and other constitutional symptoms often leads to misdiagnosis of this condition as a case of pulmonary Tuberculosis. This was also seen in our case series. This problem has been highlighted in other previous case series on ABPA. Agrawal et al, in their large case series on ABPA reported that 46.8% of the patients had history of treatment for pulmonary Tuberculosis.

Similarly, Chakrabarti et al and Shah et al from India reported that 29% and 81% of their patient had history of treatment for Tuberculosis respectively. In laboratory investigations the most useful tests were Serum IgE level, which was elevated in 100% of our patients. Aspergillus specific IgE level was also high in 100% of our patients. Similarly, 73.3% of our patients had absolute eosinophil count more than 1000. This finding was consistent with case series published by Kumar and Gaur in 2000. They found that 100% of their patients had elevated serum IgE level and positive Aspergillus specific IgE level respectively. Central bronchiectasis has been reported in 73.1% of patients with ABPA. Different case series on ABPA have reported the presence of central bronchiectasis in 69 to 99% of patients.

All of our patients were treated with inhaled bronchodilator and oral glucocorticoid. 80% of our patients underwent long term remission on subsequent follow up whereas 20% had one or more relapses of disease. The patients, who had relapse, were treated with antifungal Itraconazole besides systemic corticosteroids. Rosenberg et al in 1977 in their case series on ABPA with 20 patients, reported 100% remission rate after treatment with corticosteroid alone. Agrawal et al in 2006 reported 20% relapse rate of ABPA in their case series of 126 patients with ABPA. The treatment outcome in our group of patients was consistent with other case series as described previously.

CONCLUSIONS

ABPA is an under recognized clinical condition in Nepal. Due to high prevalence of Pulmonary Tuberculosis and Bronchial Asthma, ABPA is often misdiagnosed with these clinical conditions. A high index of clinical suspicion and relevant investigations leads to the diagnosis of ABPA. Once diagnosed, treatment with systemic steroids and inhaled bronchodilators leads to excellent clinical outcome.

REFERENCES


